GSK leans on respiratory franchise with Trelegy share-grab by Kyle Blankenship Wednesday, October 30, 2019 Thanks to a market-share grab for triple-drug COPD therapy Trelegy Ellipta, GSK's respiratory strategy is working as planned.
FDA rejects AZ's COPD triplet Breztri by Angus Liu Tuesday, October 1, 2019 Hoping to revive the case, AstraZeneca said it will submit results from another phase 3 trial that weren't originally included in its application.
AZ amps up respiratory battle with Breztri trial win by Kyle Blankenship Wednesday, August 28, 2019 AstraZeneca and GlaxoSmithKline have locked horns in their battle for respiratory supremacy. Could a trial win and an FDA nod help give AZ a leg up?
New respiratory drugs, Shingrix help GSK weather Advair generics by Angus Liu Wednesday, July 24, 2019 GKS's respiratory franchise holds its ground amid Advair generic attack, as its oncology business takes shape.
AstraZeneca's COPD triplet tees up fight with GSK's Trelegy by Angus Liu Wednesday, June 19, 2019 Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.
Pharma TV ads get groovy with '70s soundtracks by Beth Snyder Bulik Monday, May 13, 2019 A handful of branded drug ads are using popular ‘70s light rock songs, both to aid recall and to reach older audiences with music from their youth.
GSK chases Trelegy asthma nod with mixed phase 3 results by Kyle Blankenship Friday, May 3, 2019 GSK has data in hand that could help Trelegy move into the asthma arena—though it's not all positive.
Boehringer Ingelheim’s Ofev takes #FierceMadness championship by Beth Snyder Bulik, Carly Helfand Monday, April 8, 2019 Boehringer Ingelheim’s ad campaign for Ofev pulled away from GlaxoSmithKline’s Trelegy to land the #FierceMadness ad tournament crown.
#FierceMadness final: It's GSK's Trelegy vs. Boehringer's Ofev by Beth Snyder Bulik, Carly Helfand Wednesday, April 3, 2019 The #FierceMadness final game is set—and it’ll be GlaxoSmithKline's Trelegy taking on Boehringer Ingelheim's Ofev for the 2019 title.
Amgen, GSK, Novartis, BI spots are the #FierceMadness Final Four by Beth Snyder Bulik, Carly Helfand Monday, April 1, 2019 #FierceMadness DTC is down to Repatha versus Trelegy, while Aimovig will take on Ofev in a short round of voting that ends Tuesday at midnight.
